SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 5,406.21 |
| Enterprise Value ($M) | 5,036.97 |
| Book Value ($M) | 1,121.13 |
| Book Value / Share | 17.09 |
| Price / Book | 4.82 |
| NCAV ($M) | 1,111.94 |
| NCAV / Share | 16.95 |
| Price / NCAV | 4.86 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.20 |
| Return on Assets (ROA) | -0.31 |
| Return on Equity (ROE) | -0.32 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 23.07 |
| Current Ratio | 23.07 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 1,179.67 |
| Assets | 1,188.86 |
| Liabilities | 67.73 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Flynn James E | |||
| 13G/A | Vanguard Group Inc | |||
| 13G/A | Paradigm Biocapital Advisors LP | 7.80 | 29.60 | |
| 13G/A | Perceptive Advisors Llc | 4.60 | 2.10 | |
| 13G | BlackRock, Inc. | 5.60 | 0.00 | |
| 13D/A | Bain Capital Life Sciences Fund II, L.P. | 4.10 | 0.00 | |
| 13G/A | Fairmount Funds Management LLC | 3.40 | -30.99 | |
| 13G/A | Fmr Llc | 14.94 | 14.51 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 40,453 | 268,769 | 15.05 | |
| 46,335 | 253,405 | 18.28 | |
| 60,066 | 272,013 | 22.08 | |
| 78,509 | 361,303 | 21.73 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| NEOG – Neogen Corporation | NKTX – Nkarta, Inc. |
| NMRA – Neumora Therapeutics, Inc. | NVAX – Novavax, Inc. |
| NXTC – NextCure, Inc. |
Financial data and stock pages provided by
Fintel.io